Kang Y, Cai Y, Zhang X, Kong X, Su J
Medical Faculty, Kunming University of Science and Technology, 650500, Kunming, Yunnan, China.
Z Rheumatol. 2017 Jun;76(5):451-457. doi: 10.1007/s00393-016-0237-5.
Rheumatoid arthritis (RA) is an autoimmune disease with progressive joint disorder. The complex interplay of genetic and environmental influences is important for the development of the disease. A growing body of evidence has shed light on the association of dysbiosis of gut microbiota with RA. Certain gut microbial strains have been shown to inhibit or attenuate immune responses in RA experimental models, suggesting that specific species among intestinal commensal bacteria may play either a pathogenic or a protective role in the development of RA. Oral intake of probiotics/prebiotics can therefore represent a therapeutic approach for RA treatment. However, the relevant scientific work has only just begun, and the available data in this field remain limited. Fortunately, utilization of new sequencing technologies allows expanded research on the association of intestinal bacterial flora and human diseases to be attempted. In this review, we summarize the role of gut microbiota in RA progression and address how specific bacterial strains regulate the immune response in disease process. Probiotics/prebiotics in the treatment of RA is also discussed.
类风湿性关节炎(RA)是一种伴有进行性关节紊乱的自身免疫性疾病。基因和环境影响之间的复杂相互作用对该疾病的发展至关重要。越来越多的证据揭示了肠道微生物群失调与RA之间的关联。在RA实验模型中,某些肠道微生物菌株已被证明可抑制或减弱免疫反应,这表明肠道共生细菌中的特定物种可能在RA的发展中起致病或保护作用。因此,口服益生菌/益生元可以作为一种治疗RA的方法。然而,相关的科学工作才刚刚开始,该领域的现有数据仍然有限。幸运的是,利用新的测序技术可以尝试扩大对肠道细菌菌群与人类疾病关联的研究。在这篇综述中,我们总结了肠道微生物群在RA进展中的作用,并阐述了特定细菌菌株在疾病过程中如何调节免疫反应。还讨论了益生菌/益生元在RA治疗中的应用。